SALT LAKE CITY, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced two upcoming poster presentations at the 2021 San Antonio Breast Cancer Symposium (SABCS) that showcase the importance of genetic testing and precision medicine as integral components of both breast cancer treatment recommendations and risk assessment.
“These studies demonstrate our ongoing commitment to excellence in scientific research and the rapid translation of this research into clinical care,” said Nicole Lambert, president, Myriad Genetics. “We appreciate the opportunity to collaborate with leaders in the industry at Mayo Clinic, Johns Hopkins, Cleveland Clinic, University of Pennsylvania and Dana Farber Cancer Institute to deliver products that provide precise and equitable care for women dealing with breast cancer risk and treatment options.”
Genomic Instability Scores to Guide Eligibility for Treatment with PARP Inhibitors Poster Title: Identifying homologous recombination deficiency in breast cancer: genomic instability score thresholds differ in breast cancer subtypes P5-13-09 Poster Session 5, December 10, 2021, 7:00 a.m. - 8:30 a.m. (CST)Presenter: Kirsten Timms
This study, with collaboration from researchers at Mayo Clinic and Johns Hopkins, assesses the differences in genomic instability score (GIS) thresholds for different types of breast cancer (triple-negative breast cancer and estrogen receptor-positive breast cancer) using the GIS for ovarian cancer as a comparator to guide the identification of potential candidates for treatment with PARP inhibitors.
Finding Ways to Improve Polygenic Risk Scores by Reducing Ancestral Bias Poster Title: Integration of an ancestry-inclusive polygenic risk score with the Tyrer-Cuzick breast cancer risk modelP2-11-21 Poster Session 2, December 8, 2021, 5:00 p.m. - 6:30 p.m. (CST)Presenter: Elisha Hughes
This study, done in collaboration with researchers from Cleveland Clinic, University of Pennsylvania, and Dana-Farber Cancer Institute, validates the integration of an ancestry-inclusive breast cancer polygenic risk score with a clinical and family history-based model in the development of a risk assessment tool that is both genomically-informed and equitable.
Follow Myriad on Twitter via @myriadgenetics and keep up to date with SABCS meeting news and updates by using the #SACBS21 hashtag.
About Myriad GeneticsMyriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and wellbeing for all, empowering individuals with vital genetic insights and enabling healthcare providers to better detect, treat and prevent disease. Myriad discovers and commercializes genetic tests that determine the risk of developing disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, MyRisk, Myriad MyRisk, MyRisk Hereditary Cancer, MyChoice, MyPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, EndoPredict, Prequel, Foresight, GeneSight, RiskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries.
Safe Harbor StatementThis press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company delivering products that provide precise and equitable care for women dealing with breast cancer risk and treatment options, the validation of integrating an ancestry-inclusive breast cancer polygenic risk score with a clinical and family history-based model in the development of a risk assessment tool and the company’s strategic imperatives under the caption "About Myriad Genetics." These “forward-looking statements” are management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks include, but are not limited to: uncertainties associated with COVID-19, including its possible effects on our operations and the demand for our products and services; risks related to our ability to efficiently and flexibly manage our business amid uncertainties associated with COVID-19; the risk that sales and profit margins of our existing molecular diagnostic tests may decline or that we may not be able to operate our business on a profitable basis; risks related to our ability to generate sufficient revenue from our existing product portfolio or in launching and commercializing new tests; risks related to changes in governmental or private insurers’ coverage and reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about the potential market opportunity for our products; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents; risks related to changes in intellectual property laws covering our molecular diagnostic tests, or patents or enforcement, in the United States and foreign countries; risks related to security breaches, loss of data and other disruptions, including from cyberattacks; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; risks related to the material weakness identified in our internal control over financial reporting, including the impact thereof and our remediation plan; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our Transition Report on Form 10-K filed with the Securities and Exchange Commission on March 16, 2021, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.